4D Molecular Therapeutics, Inc. Share Price & Technical Analysis
FDMT · $8.64 (+0.47%)
Healthcare / Biotechnology
$8.64
+0.47%
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of…
Price chart
Seasonality
May has 2 positive and 2 negative years (last 5 years shown)
-3% return in May, 2% avg return in past 3 year May month.
20% return in 2026, -14% avg return in past 3 years.
Swipe sideways to see all months →
| Jan | Feb | Mar | Apr | May | Jun | Jul | Aug | Sep | Oct | Nov | Dec | Yr | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 26 | 17% | 11% | 1% | -6% | -3% | – | – | – | – | – | – | – | 20% |
| 25 | -2% | -17% | -30% | 6% | 3% | 3% | 18% | 17% | 45% | 34% | 1% | -34% | 44% |
| 24 | -14% | 62% | 11% | -25% | 0% | -14% | -16% | -16% | -28% | -26% | -4% | -28% | -97% |
| 23 | -9% | -9% | -11% | 5% | 2% | -1% | 2% | -10% | -23% | -15% | 19% | 60% | 11% |
| 22 | -29% | -14% | 9% | -21% | -36% | -9% | 34% | -15% | 1% | 6% | 175% | -9% | 93% |
Monthly return % by calendar month · historical pattern, not a forecast
Bearish · Emerging · Neutral
4D Molecular Therapeutics, Inc., a late-stage biotechnology company, engages in the development of adeno-associated virus vectors from its proprietary synthetic vector discovery platform, Therapeutic Vector Evolution in the Netherlands and the United States. The company's lead product candidate is 4D-150 for the treatment of retinal vascular diseases by providing multi-year sustained production of anti-VEGF from the retina with intravitreal injection, as well as for treating wet age-related macular degeneration and diabetic macular edema. It is also developing 4D-710, which is in early-stage study for the treatment of cystic fibrosis; 4D-175 that is in preclinical stage for treating geographic atrophy; and 4D-725, which is in preclinical stage for the treatment of alpha-1 anti-trypsin deficiency lung disease. 4D Molecular Therapeutics, Inc. has collaboration and licensing agreements with Otsuka Pharmaceutical Co., Ltd. The company was founded in 2013 and is headquartered in EmeryVille, California.
Full AI Q&A, portfolio tracking, and live alerts in the app.
Key metrics
Market cap
$545.24M
P/E ratio
—
52W high
$12.34
52W low
$3.37
Volume
2,28,696
Beta
2.76
Related stocks in Healthcare
Merck & Co Inc Cedear (5…
₹32,900
Abbott Laboratories Cede…
₹30,500
Eli Lilly And Company Ce…
₹25,540
Unitedhealth Group Inc C…
₹17,200
₹6,600
Frequently asked questions
- What is 4D Molecular Therapeutics, Inc. share price today?
- 4D Molecular Therapeutics, Inc. (FDMT) last traded around $8.64 on StockPro. Prices refresh every few minutes during market hours.
- What technical signals does FDMT have?
- StockPro monitors breakouts, volume spikes, EMA reversals, and momentum for FDMT. Download the app for real-time alerts.
- How can I analyze 4D Molecular Therapeutics, Inc. stock?
- Use the price chart, seasonality heatmap, key metrics, and AI insight on this page. For portfolio tracking and push alerts, download StockPro on Android or iOS.